A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.
These paid lobbying efforts on behalf of industry are carried out under the pretext of advocacy in the public interest.
Dr. Diane M. Harper, a lead researcher in the development of the humanpapilloma virus vaccine, who says giving the drug to 11-year-old girls "is a great big public health experiment."
What does the "Gillberg affair" suggest about the integrity of the data underlying the DAMP-ADHD hypothesis?
"The federal government's campaign could discourage potential quitters who don't want to spend money on quitting aids or don't like the idea of treating their nicotine addiction with more nicotine."
The WSJ confirms that Merck is "desperate" for funding streams and "vaccination across the U.S. would make Gardasil an automatic blockbuster."
In essence FDA proposals merely change the seating arrangement on the deck of the sinking Titanic. Eli Lilly announced that it intends to seek FDA approval for a long-lasting injectable form of Zyprexa (taken once a month).
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
Two Press Briefings are planned to demonstrate the multiple flaws in FDA's methodology and to provide credible science-based information.
